Endometrial cancer is the most common gynecologic malignancy in Europe and usually diagnosed in its initial stage owing to early symptoms of abnormal bleeding. There is no population screening for this disease, although it can sometimes be accidentally diagnosed in asymptomatic patients. Our study aims to determine differences in clinical and tumor characteristics between an asymptomatic and symptomatic group of patients. This unicentric prospective observational study took place in University Hospital Brno between January 2016 and December 2019. A total of 264 patients met inclusion criteria (26% asymptomatic, 74% with reported symptoms). We did not find a statistically significant difference in clinical characteristics (menopausal status, parity, age, BMI, and serum level of CA 125) between groups. According to ultrasound examination, bleeding tumors were larger (19.5 vs. 12.7 mm, p ≤ 0.001). Definitive histology results indicated more frequent lymphovascular space invasion (p < 0.001), along with deep myometrial (p = 0.001) and cervical (p = 0.002) invasion. There was no difference in advanced stages of the tumor. We did not substantiate statistically significant difference in immunohistochemical profile (estrogen and progesterone receptors, L1 cell adhesion molecule, tumor protein p53), which is relevant for tumor recurrence risk and survival capacity. Our conclusions affirmed that bleeding occurs more often among patients with local tumor invasion into the myometrium and cervical stroma. Final International Federation of Gynecology and Obstetrics (FIGO) stage, histology, and immunohistochemical characteristics do not significantly affect symptom appearance.

Department of Gynecology and Obstetrics University Hospital Brno Masaryk University 60177 Brno Czech Republic

Department of Internal Medicine Hematology and Oncology University Hospital Brno Masaryk University 60177 Brno Czech Republic

Department of Pathology University Hospital Brno Masaryk University 60177 Brno Czech Republic

Faculty of Medicine Institute of Biostatistics and Analyses Masaryk University 60177 Brno Czech Republic

See more in PubMed

Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. PubMed DOI

Colombo N., Creutzberg C., Amant F., Bosse T., González-Martín A., Ledermann J., Marth C., Nout R., Querleu D., Mirza M.R., et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Int. J. Gynecol. Cancer. 2016;27:16–41. doi: 10.1097/IGC.0000000000000609. PubMed DOI PMC

Concin N., Matias-Guiu X., Vergote I., Cibula D., Mirza M.R., Marnitz S., Ledermann J., Bosse T., Chargari C., Fagotti A., et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer. 2021;31:12–39. doi: 10.1136/ijgc-2020-002230. PubMed DOI

Levine D.A., The Cancer Genome Atlas Research Network Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73. doi: 10.1038/nature12113. PubMed DOI PMC

Stelloo E., Nout R.A., Osse E.M., Jürgenliemk-Schulz I.J., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., Nijman H.W., Putter H., Bosse T., et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin. Cancer Res. 2016;22:4215–4224. doi: 10.1158/1078-0432.CCR-15-2878. PubMed DOI

León-Castillo A., de Boer S.M., Powell M.E., Mileshkin L.R., Mackay H.J., Leary A., Nijman H.W., Singh N., Pollock P.M., Bessette P., et al. Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit from Adjuvant Therapy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2020;38:3388–3397. doi: 10.1200/JCO.20.00549. PubMed DOI PMC

Asano H., Hatanaka K.C., Matsuoka R., Dong P., Mitamura T., Konno Y., Kato T., Kobayashi N., Ihira K., Nozaki A., et al. L1CAM Predicts Adverse Outcomes in Patients with Endometrial Cancer Undergoing Full Lymphadenectomy and Adjuvant Chemotherapy. Ann. Surg. Oncol. 2020;27:2159–2168. doi: 10.1245/s10434-019-08103-2. PubMed DOI

Zeimet A.G., Reimer D., Huszar M., Winterhoff B., Puistola U., Abdel Azim S., Müller-Holzner E., Ben-Arie A., Van Kempen L.C., Petru E., et al. L1CAM in early-stage type I endometrial cancer: Results of a large multicenter evaluation. J. Natl. Cancer Inst. 2013;105:1142–1150. doi: 10.1093/jnci/djt144. PubMed DOI

Zhang Y., Zhao D., Gong C., Zhang F., He J., Zhang W., Zhao Y., Sun J. Prognostic role of hormone receptors in endometrial cancer: A systematic review and meta-analysis. World J. Surg. Oncol. 2015;13:208. doi: 10.1186/s12957-015-0619-1. PubMed DOI PMC

Smith D., Stewart C.J.R., Clarke E.M., Lose F., Davies C., Armes J., Obermair A., Brennan D., Webb P.M., Nagle C.M., et al. ER and PR expression and survival after endometrial cancer. Gynecol. Oncol. 2018;148:258–266. doi: 10.1016/j.ygyno.2017.11.027. PubMed DOI

Trovik J., Wik E., Werner H.M.J., Krakstad C., Helland H., Vandenput I., Njolstad T.S., Stefansson I.M., Marcickiewicz J., Tingulstad S., et al. Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial. Eur. J. Cancer Oxf. Engl. 1990. 2013;49:3431–3441. doi: 10.1016/j.ejca.2013.06.016. PubMed DOI

Weinberger V., Bednarikova M., Hausnerova J., Ovesna P., Vinklerova P., Minar L., Felsinger M., Jandakova E., Cihalova M., Zikan M. A Novel Approach to Preoperative Risk Stratification in Endometrial Cancer: The Added Value of Immunohistochemical Markers. Front. Oncol. 2019;9 doi: 10.3389/fonc.2019.00265. PubMed DOI PMC

Leone F.P.G., Timmerman D., Bourne T., Valentin L., Epstein E., Goldstein S.R., Marret H., Parsons A.K., Gull B., Istre O., et al. Terms, definitions and measurements to describe the sonographic features of the endometrium and intrauterine lesions: A consensus opinion from the International Endometrial Tumor Analysis (IETA) group. Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol. 2010;35:103–112. doi: 10.1002/uog.7487. PubMed DOI

van der Putten L.J., Visser N.C., van de Vijver K., Santacana M., Bronsert P., Bulten J., Hirschfeld M., Colas E., Gil-Moreno A., Garcia A., et al. L1CAM expression in endometrial carcinomas: An ENITEC collaboration study. Br. J. Cancer. 2016;115:716–724. doi: 10.1038/bjc.2016.235. PubMed DOI PMC

Weiderpass E., Antoine J., Bray F.I., Oh J.-K., Arbyn M. Trends in corpus uteri cancer mortality in member states of the European Union. Eur. J. Cancer Oxf. Engl. 1990. 2014;50:1675–1684. doi: 10.1016/j.ejca.2014.02.020. PubMed DOI

Setiawan V.W., Yang H.P., Pike M.C., McCann S.E., Yu H., Xiang Y.B., Wolk A., Wentzensen N., Weiss N.S., Webb P.M., et al. Type I and II Endometrial Cancers: Have They Different Risk Factors? J. Clin. Oncol. 2013;31:2607–2618. doi: 10.1200/JCO.2012.48.2596. PubMed DOI PMC

Lee N.K., Cheung M.K., Shin J.Y., Husain A., Teng N.N., Berek J.S., Kapp D.S., Osann K., Chan J.K. Prognostic factors for uterine cancer in reproductive-aged women. Obstet. Gynecol. 2007;109:655–662. doi: 10.1097/01.AOG.0000255980.88205.15. PubMed DOI

Shaw E., Farris M., McNeil J., Friedenreich C. Obesity and Endometrial Cancer. Obes. Cancer. 2016;208:107–136. doi: 10.1007/978-3-319-42542-9_7. PubMed DOI

Raglan O., Kalliala I., Markozannes G., Cividini S., Gunter M.J., Nautiyal J., Gabra H., Paraskevaidis E., Martin-Hirsch P., Tsilidis K.K., et al. Risk factors for endometrial cancer: An umbrella review of the literature. Int. J. Cancer. 2019;145:1719–1730. doi: 10.1002/ijc.31961. PubMed DOI

Reijnen C., Visser N.C., Kasius J.C., Boll D., Geomini P.M., Ngo H., Van Hamont D., Pijlman B.M., Vos M.C., Bulten J., et al. Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: A multicenter prospective cohort study. J. Gynecol. Oncol. 2019;30:e70. doi: 10.3802/jgo.2019.30.e70. PubMed DOI PMC

Clarke M.A., Long B.J., Del Mar Morillo A., Arbyn M., Bakkum-Gamez J.N., Wentzensen N. Association of Endometrial Cancer Risk With Postmenopausal Bleeding in Women. JAMA Intern. Med. 2018;178:1210–1222. doi: 10.1001/jamainternmed.2018.2820. PubMed DOI PMC

Pennant M., Mehta R., Moody P., Hackett G., Prentice A., Sharp S.J., Lakshman R. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG Int. J. Obstet. Gynaecol. 2017;124:404–411. doi: 10.1111/1471-0528.14385. PubMed DOI PMC

Ferrazzi E., Zupi E., Leone F.P., Savelli L., Omodei U., Moscarini M., Barbieri M., Cammareri G., Capobianco G., Cicinelli E., et al. How often are endometrial polyps malignant in asymptomatic postmenopausal women? A multicenter study. Am. J. Obstet. Gynecol. 2009;200:235.e1–6. doi: 10.1016/j.ajog.2008.09.876. PubMed DOI

Jokubkiene L., Sladkevicius P., Valentin L. Transvaginal ultrasound examination of the endometrium in postmenopausal women without vaginal bleeding. Ultrasound Obstet. Gynecol. 2016;48:390–396. doi: 10.1002/uog.15841. PubMed DOI

Smith-Bindman R., Weiss E., Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmenopausal women without vaginal bleeding. Ultrasound Obstet. Gynecol. Off. J. Int. Soc. Ultrasound Obstet. Gynecol. 2004;24:558–565. doi: 10.1002/uog.1704. PubMed DOI

Alcázar J.L., Bonilla L., Marucco J., Padilla A.I., Chacón E., Manzour N., Salas A. Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥11 mm: A systematic review and meta-analysis. J. Clin. Ultrasound. 2018;46:565–570. doi: 10.1002/jcu.22631. PubMed DOI

Lieng M., Istre O., Qvigstad E. Treatment of endometrial polyps: A systematic review. Acta Obstet. Gynecol. Scand. 2010;89:992–1002. doi: 10.3109/00016349.2010.493196. PubMed DOI

Wong M., Crnobrnja B., Liberale V., Dharmarajah K., Widschwendter M., Jurkovic D. The natural history of endometrial polyps. Hum. Reprod. Oxf. Engl. 2017;32:340–345. doi: 10.1093/humrep/dew307. PubMed DOI

Uglietti A., Buggio L., Farella M., Chiaffarino F., Dridi D., Vercellini P., Parazzini F. The risk of malignancy in uterine polyps: A systematic review and meta-analysis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2019;237:48–56. doi: 10.1016/j.ejogrb.2019.04.009. PubMed DOI

Gemer O., Segev Y., Helpman L., Hag-Yahia N., Eitan R., Raban O., Vaknin Z., Leytes S., Arie A.B., Amit A., et al. Is there a survival advantage in diagnosing endometrial cancer in asymptomatic postmenopausal patients? An Israeli Gynecology Oncology Group study. Am. J. Obstet. Gynecol. 2018;219:181.e1–181.e6. doi: 10.1016/j.ajog.2018.05.013. PubMed DOI

Van der Putten L.J.M., Visser N.C.M., van de Vijver K., Santacana M., Bronsert P., Bulten J., Hirschfeld M., Colas E., Gil-Moreno A., Garcia A., et al. Added Value of Estrogen Receptor, Progesterone Receptor, and L1 Cell Adhesion Molecule Expression to Histology-Based Endometrial Carcinoma Recurrence Prediction Models: An ENITEC Collaboration Study. Int. J. Gynecol. Cancer. 2018;28:514–523. doi: 10.1097/IGC.0000000000001187. PubMed DOI

Köbel M., Ronnett B.M., Singh N., Soslow R.A., Gilks C.B., McCluggage W.G. Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. Int. J. Gynecol. Pathol. 2019;38(Suppl. 1):S123–S131. doi: 10.1097/PGP.0000000000000488. PubMed DOI PMC

van Weelden W.J., Reijnen C., Küsters-Vandevelde H.V.N., Bulten J., Bult P., Leung S., Visser N.C., Santacana M., Bronsert P., Hirschfeld M., et al. The cutoff for estrogen and progesterone receptor expression in endometrial cancer revisited: A European Network for Individualized Treatment of Endometrial Cancer collaboration study. Hum. Pathol. 2021;109:80–91. doi: 10.1016/j.humpath.2020.12.003. PubMed DOI

Barak F., Kalichman L., Gdalevich M., Milgrom R., Laitman Y., Piura B., Lavie O., Gemer O. The influence of early diagnosis of endometrioid endometrial cancer on disease stage and survival. Arch. Gynecol. Obstet. 2013;288:1361–1364. doi: 10.1007/s00404-013-2898-5. PubMed DOI

Does an Endometrial Cancer Diagnosis among Asymptomatic Patients Improve Prognosis?